Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders
Switzerland / USA
Joined July 2021
- Tweets25
- Following336
- Followers76
- Likes18
@asceneuron_sa joins @CPathInstitute 's ‘Critical Path Alzheimer’s Disease’ Consortium.
With our highly experienced team, novel pipeline, and promising emerging datasets, we are excited to begin contributing as the consortium advances tau-PET as a biomarker!
Asceneuron SA retweeted
Meet the esteemed members of the first #PanelDiscussion of the #20thAnglonordic.
Register Now: lnkd.in/ds-qUya
Chaired by #LisaUrquhart, the panel will cover #Neurodegeneration with members from @MISSIONTherapeu, @asceneuron_sa, @alchemabtx and #VesperBio.
#LifeSciences
@asceneuron_sa expands its Scientific Advisory Board, with the appointments of Dr Samantha Budd Haeberlein, Henrik Zetterberg, @RikOssenkoppele , and Chris van Dyck, MD to support Phase II development of its lead asset ASN51 in #Alzheimers Disease.
👉asceneuron.com/news/asceneur…
For more information on the new appointments and their experiences, read the full press release here: asceneuron.com/news/asceneur…
@Aseceneuron_sa is pleased to appoint industry veteran Abbas Hussain as its new Chair to its Board at a pivotal time of growth & development.
Learn more about Abbas’ experience and successes👉 asceneuron.com/news/abbas-hu…
#parkinsons #alzheimers #tauopathies #companygrowth
#Asceneuron_sa is delighted to announce the appointment of Barbara Angehrn Pavik as the new Chief Executive Officer (CEO)
👉businesswire.com/news/home/2…
Looking forward to connect with pharmaceutical executives to explore partnering and strategic opportunities in #Alzheimer disease at #BIO2023!
👉asceneuron.com/news/asceneur…
ALT Asceneuron to attend BIO International Convention in Boston!
This licensing agreement with Ferrer is important news for patients suffering from PSP and their families. Asceneuron, as a neurodegeneration-focused company, will continue expanding the application of OGA mechanism in other diseases in addition to... businesswire.com/news/home/2…
#AsceneuronSA is delighted to announce the acquisition of ASN90 worldwide rights by #ferrer, to treat Progressive Supranuclear Palsy (PSP).
asceneuron.com/news/ferrer-a…
#curepsp
#ProgressiveSupranuclearPalsy #NeurodegenerativeDiseases
#rarediseaseday2023
#rarediseaseday
Looking forward to meeting you at the Annual Biotech in Europe Forum today in Basel!
#Asceneuron_SA CEO #DirkBeher will take part in the “CNS: Focus on Neurodegenerative Diseases” panel discussion scheduled at 12:05 PM, Room Ballroom.
#Sachs_BEF #Sachs_SALSW
Join us at the #ASBMB O-GlcNAc conference on July 7–10, 2022 at the University of Georgia, Athens, Ga, USA!
Our team will present ASN51, which has best-in-class potential to treat #Alzheimer’s Disease & other related neurodegenerative diseases.
Program:asbmb.org/meetings-events/o-…
ALT Asceneuron at ASBMB OGA conference, July 7-10, 2022, Athens, Ga
Asceneuron SA retweeted
La société lausannoise @asceneuron_sa , spin-off du groupe Merck Serono, a levé des dizaines de millions de francs pour s’attaquer à aux maladies de l’alzheimer et de Parkinson. Deux molécules prometteuses sont dans le pipeline. bilan.ch/story/asceneuron-se…
Asceneuron SA retweeted
Les molécules développées par @asceneuron_sa sont dirigées contre une enzyme (O-GlcNAcase ou OGA) qui élimine des sucres à la surface des protéines tau — sucre qui favorise leur agrégation heidi.news/innovation-soluti…
#Asceneuron_SA has been awarded a second grant from The Michael J. Fox Foundation for Parkinson's Research (#MJFF) to accelerate the study of its clinical stage O-GlcNAcase inhibitor ASN51 as a potential new treatment for #Parkinsons disease.
More: asceneuron.com/news/asceneur…
While more than 7 million people live with Parkinson's disease, currently available treatments are symptomatic.
@asceneuron_sa develops small molecules having the potential to deliver disease-modifying drugs to treat Parkinson’s disease.
#ParkinsonsAwarenessWeek #FutureOfPD.
We are pleased to announce that @ACSPublications has published @asceneuron_sa’s pioneering #preclinical efficacy data on our novel #clinical molecule #ASN90 in both #Alzheimers and #Parkinsons disease models.
More: bit.ly/3wUqZ7f
#research #neurodegenerativediseases
Asceneuron SA retweeted
22nd International Conference on Alzheimer's Drug Discovery
1⃣ Clinical Trials & Novel Approaches for #Dementia
2⃣ Start-up Forum
3⃣Advances in Fluid Biomarkers
4⃣ Drug Development Approaches for Frontotemporal Dementia
Register➡️meetings.alzdiscovery.org/al…
#AlzDiscovery #Alzheimers
CEO Dirk Beher will be presenting "OGA inhibitors as multimodal drugs for intracellular proteinopathies", at the 22nd International Conference on Alzheimer’s Drug Discovery today at 10:45am ET.
Programme information: bit.ly/3uqdfhh
#ADDF2021 #alzheimers @TheADDF
ALT 22nd International Conference on Alzheimer's Drug Discovery https://meetings.alzdiscovery.org/alz-program/
@asceneuron_sa to present data on its O-GlcNAcase inhibitor pipeline at the below conferences
@TheADDF
04/10/21 - 16:45 CET
@TheNewANA1
18/10/21 - 23:30 CET
#EUROTAU
26/10/21 - 14:55 CET
#alzheimers #neurodegenerativediseases #OGA # #ADDF2021 #ANA2021 #eurotau2021
